The cytokine network

doi:10.1016/0167-5699(89)90085-6

Immunology Today

Volume 10, Issue 9, September 1989, Pages 299-304

Immunology Today

https://doi.org/10.1016/0167-5699(89)90085-6 Get rights and content

Abstract

The availability of pure recombinant cytokines and molecular probes for their genes has generated an avalanche of scientific information. These data show that cytokines have a broad and overlapping range of cell regulatory activity both in vitro and in vivo. New factors are added to the cytokine list, and new functions reported for existing cytokines, with such frequency that it is difficult to retain an overall picture. With this problem in mind, a large wallchart was designed and was displayed at the second meeting of the British Cytokine Group^∗ whose members pooled their collective knowledge, to list the known biological activities of these cytokines. This wallchart of cytokine activity, now referenced, is reproduced for Immunology Today. It is not a final list: new information and cytokines are continually reported and space has been left for readers to make their own additions. A neutrophil-activating peptide variously named monocyte-derived neutrophil chemotactic factor (MDNCF), neutrophil-activating factor (NAF), lymphocyte-derived neutrophil-activating peptide (LYNAP), which has been suggested as a candidate for interleukin 8 (IL-8), is included.

References (132)

D.A. Weigent et al.
Biochem. Biophys. Res. Commun.
(1983)
A. Kist et al.
Blood
(1988)
R.B. Herberman
Immunol. Today
(1987)
F. Rosa et al.
Immunol. Today
(1984)
M.R. Capobianchi et al.
Hum. Immunol.
(1985)
J. Gordon et al.
Immunol. Today
(1987)
J.P. Siegel
Cell. Immunol.
(1988)
C.S. Henney
Immunol. Today
(1989)
M. Kriegler et al.
Cell
(1988)
B.R.G. Williams et al.

J. Mestan et al.

Nature

(1986)

J. Le et al.

Lab. Invest.

(1987)

F.R. Balkwill

Cytokines in Cancer Therapy

(1989)

C.E. Brinckeroff et al.

J. Immunol.

(1985)

A. Zlotnick et al.

C.J. Sanderson et al.

J. Exp. Med.

(1985)

A.E. Namen et al.

Nature

(1988)

D. Metcalf

Blood

(1986)

M.B. Sporn et al.

J. Cell Biol.

(1987)

E.C. Borden et al.

Cancer Res.

(1982)

F.R. Balkwill

L. Fransen et al.

Science

(1986)

R. Aiyer et al.

K. Onozaki et al.

J. Immunol.

(1985)

L. Chen et al.

J. Le et al.

Int. J. Cancer

(1984)

C.A. Dinarello et al.

New Engl. J. Med.

(1987)

J.E. Talmadge et al.

Cancer Res

(1988)

M. Malkovsky

Nature

(1987)

W.E. Paul et al.

Annu. Rev. Immunol.

(1987)

M.R. Shalaby et al.

J. Immunol.

(1985)

N.H. Ruddle

J. Immunol.

(1986)

M. Thelen et al.

FASEB J.

(1988)

J.A. Sosman et al.

J. Natl Cancer Inst.

(1988)

K.J.I. Thorne et al.

Eur. J. Immunol.

(1986)

D. Silberstein et al.

M.E. Rothenburg et al.

J. Clin. Invest.

(1988)

M.A. Vadas et al.

Lymphokines

(1985)

A.F. Lopez et al.

J. Clin. Invest.

(1986)

M.J. Brunda et al.

Int. J. Cancer

(1986)

M.J. Brunda et al.

Cancer Res.

(1986)

T. Kalland

J. Immunol.

(1987)

A.H. Rook et al.

J. Immunol.

(1986)

S. Sone et al.

J. Natl Cancer Inst.

(1988)

E.A. Grimm et al.

J. Exp. Med.

(1982)

G. Gallagher et al.

Clin. Exp. Immunol.

(1988)

J.J. Mule et al.

J. Exp. Med.

(1987)

M.B. Widmer et al.

J. Exp. Med.

(1987)

T. Espevik et al.

J. Immunol.

(1988)

T. Collins et al.

Cited by (688)

The effect of topical magnesium on healing of pre-clinical burn wounds
2024, Burns
Magnesium (Mg) is an essential factor in the healing process. This study aimed to evaluate the effect of Mg creams on healing burn wounds in the rat model.
To induce burns under general anaesthesia, a 2 × 2 cm2, 100 °C plate was placed for 12 s between the scapulas in 100 male adult Sprague Dawley rats. Animals were divided into five groups (n = 20); positive control (induced burn without treatment); vehicle control (received daily Eucerin cream base topically); comparative control (induced burn and treated daily with Alpha burn cream topically); Treatment 1 and 2 (received daily Mg cream 2% and 4% topically, respectively). All animals were bled for hematological assessment of malondialdehyde (MDA) and TNF-α and sacrificed on days 0, 1, 7, 14, and 21 after interventions for biomechanical, histological, and stereological studies.
Stereologically speaking, in treatment groups an increase in dermal collagen volume and fibroblasts was noticed. In treatment groups, the length of vessels, angiogenesis, and skin stretch increased, but the wound area, MDA, and TNF-α level decreased.
Mg cream was effective in healing burns.
Designing a bioadjuvant candidate vaccine targeting infectious bursal disease virus (IBDV) using viral VP2 fusion and chicken IL-2 antigenic epitope: A bioinformatics approach
2023, Computers in Biology and Medicine
Infectious Bursal Disease (IBD) is a common and contagious viral infection that significantly affects the poultry industry. This severely suppresses the immune system in chickens, thereby threating their health and well-being. Vaccination is the most effective strategy for preventing and controlling this infectious agent. The development of VP2-based DNA vaccines combined with biological adjuvants has recently received considerable attention due to their effectiveness in eliciting both humoral and cellular immune responses. In this study, we applied bioinformatics tools to design a fused bioadjuvant candidate vaccine from the full-length sequence of the VP2 protein of IBDV isolated in Iran using the antigenic epitope of chicken IL-2 (chiIL-2). Furthermore, to improve the antigenic epitope presentation and to maintain the three-dimensional structure of the chimeric gene construct, the P2A linker (L) was used to fuse the two fragments.
Our in-silico analysis for the design of a candidate vaccine indicates that a continuous sequence of amino acid residues ranging from 105 to 129 in chiIL-2 is proposed as a B cell epitope by epitope prediction servers. The final 3D structure of the VP2-L-chiIL-2_105-129 was subjected to physicochemical property determination, molecular dynamic simulation, and antigenic site determination. The results of these analyses led to the development of a stable candidate vaccine that is non-allergenic and has the potential for antigenic surface display potential and adjuvant activity. Finally, it is necessary to investigate the immune response induced by our proposed vaccine in avian hosts. Notably, increasing the immunogenicity of DNA vaccines can be achieved by combining antigenic proteins with molecular adjuvants using the principle of rational vaccine design.
Molecular cloning, expression analysis and immune-related functional identification of tumor necrosis factor alpha (TNFα) in Sepiella japonica under bacteria stress
2023, Fish and Shellfish Immunology
Citation Excerpt :
Cytokines, which are synthesized and secreted by immune cells and some non-immune cells upon stimulation including tumor necrosis factors, interferons, interleukins, colony-stimulating factors, and others, have specific effects on cellular interactions and communication as a class of small molecule proteins with comprehensive biological activity [1,2].
Tumor necrosis factor α (TNFα), a cytokine mainly secreted by active macrophages and monocytes, causes hemorrhagic necrosis of tumor tissues, kills tumor cells, regulates inflammatory responses, and plays a crucial role in innate immunity. In this study, TNFα of Sepiella japonica (named as SjTNFα) was acquired, whose full-length cDNA was 1206 bp (GenBank accession no. ON357428), containing a 5′ UTR of 185 bp, a 3′ UTR of 137 bp and an open reading frame (ORF) of 1002bp to encode a putative peptide of 333 amino acids for constructing the transmembrane domain and the cytoplasmic TNF domain. Its predicted pI was 8.69 and the theoretical molecular weight was 44.72 KDa. Multiple sequence alignment and phylogenetic analysis showed that SjTNFα had the highest homology to Octopus sinensis, they fell into a unified branch and further clustered with other animals. Real-time PCR indicated that SjTNFα was widely expressed in all subject tissues, including spleen, pancreas, gill, heart, brain, optic lobe, liver and intestine, and exhibited the highest in the liver and the lowest in the brain. The relative expression of SjTNFα varied at the developmental period of juvenile stage, pre-spawning and oviposition in the squid, with the highest in the liver at the juvenile stage and oviposition, and in the optic lobe of pre-spawning. After being infected with Vibrio parahaemolyticus and Aeromonas hydrophila, the expression of SjTNFα in liver and gill were both upregulated with time, and the highest expression appeared at 24 h and 8 h in liver for different infection, and at 4 h in gill consistently. Cell localization showed that SjTNFα distributed on membrane of HEK293 cells because it was a type II soluble transmembrane protein. When HEK293 cells were stimulated with LPS of different concentrations, the NF-κB pathway was activated in the nucleus and the corresponding mRNA was transferred through the intracellular signal transduction pathway, resulting in the synthesis and release of TNFα, which made the expression of SjTNFα was up-regulated obviously. These findings showed that SjTNFα might play an essential role in the defense of S. japonica against bacteria challenge, which contributed to the understanding of the intrinsic immune signaling pathway of Cephalopoda and the further study of host-pathogen interactions.
Gene cloning and functional study of PmKSPI from Pinctada fucata martensii
2022, Fish and Shellfish Immunology
Kunitz-type serine protease inhibitors (KSPI) are a family of serine protease inhibitors (SPIs) and are extensively found in animals, plants, and microbes. SPI can inhibit proteases that may be harmful or unwanted to its cells. Here, a four-domain Kunitz-type SPI, PmKSPI, was cloned by RACE in the pearl oyster Pinctada fucata martensii. The full-length cDNA sequence of PmKSPI was 1318 bp, including the 5′ UTR (25 bp), the 3′ UTR (96 bp) and ORF (1197 bp). Homology analysis indicated that PmKSPI had the highest resemblance (30.14%) with its homolog in Crassostrea gigas. Phylogenetic analysis revealed that PmKSPI clustered with homologs in other molluscs. We found that PmKSPI mRNA expression in P. f. martensii was distributed in all six tissues, with the highest level in the mantle, and almost no expression in other tissues. After PAMPs challenge, expression of PmKSPI mRNA in the mantle was significantly up-regulated. The recombinant protein rPmKSPI significantly inhibited the growth of 5 kinds of Gram-negative bacteria but had little effect on Gram-positive bacterial activity. Transmission electron microscopy showed that plasmolysis occurred in two Gram-negative bacteria species when treated with rPmKSPI. rPmKSPI may thus have a bactericidal effect by destroying the bacterial cell membrane or cell walls and releasing its contents. Therefore, our results suggest that PmKSPI is tightly associated with the immunological defence of P. f. martensii.
Interleukin-8: An evolving chemokine
2022, Cytokine
Citation Excerpt :
Mouse homologues share from 40 to 90% homology with one another and human IL-8. IL-8 is produced by many cell types including monocytes, lymphocytes, granulocytes, fibroblasts, endothelial cells, epithelial cells, hepatocytes, mesangial cells and chondrocytes and is released only under inflammatory conditions [42,44]. Even platelets store IL-8 in their granules and rapidly release IL-8 in inflammation [45].
Early in the 1980s several laboratories mistakenly reported that partially purified interleukin-1 (IL-1) was chemotactic for neutrophils. However, further investigations by us, revealed that our purified IL-1 did not have neutrophil chemotactic activity and this activity in the LPS-stimulated human monocyte conditioned media could clearly be separated from IL-1 activity on HPLC gel filtration. This motivated Teizo Yoshimura and Kouji Matsushima to purify the monocyte-derived neutrophil chemotactic factor (MDNCF), present in LPS conditioned media and molecularly clone the cDNA for MDNCF. They found that MDNCF protein (later renamed IL-8, and finally termed CXCL8) is first translated as a precursor form consisting of 99 amino acid residues and the signal peptide is then removed, leading to the secretion and processing of biologically active IL-8 of 72 amino acid form (residues 28–99). There are four cysteine residues forming two disulfide linkage and 14 basic amino acid residues which result in a very basic property for the binding of IL-8 to heparan sulfate-proteoglycan. The IL-8 gene consists of 4 exons and 3 introns. IL-8 is produced by various types of cells in inflammation. The 5′-flanking region of IL-8 gene contains several nuclear factor binding sites, and NF-κB in combination with AP-1 or C/EBP synergistically activates IL-8 gene in response to IL-1 and TNFα.
Two receptors exist for IL-8, CXCR1 and CXCR2 in humans, which belong to γ subfamily of GTP binding protein (G-protein) coupled rhodopsin-like 7 transmembrane domain receptors. Rodents express CXCR2 and do not produce IL-8, but produce numerous homologues instead. Once IL-8 binds to the receptor, β and γ subunits of G-protein are released from Gα (Gαi2 in neutrophils) and activate PI3Kγ, PLCβ2/β3, PLA2 and PLD. Gαi2 inhibits adenyl cyclase to decrease cAMP levels. Small GTPases Ras/Rac/Rho/cdc42/Rap1, PKC and AKT (PKB) exist down-stream of β and γ subunits and regulate cell adhesion, actin polymerization, membrane protrusion, and eventually cell migration. PLCβ activation generates IP3 and induces Ca⁺⁺ mobilization, DAG generation to activate protein kinase C to lead granule exocytosis and respiratory burst.
MDNCF was renamed interleukin 8 (IL-8) at the International Symposium on Novel Neutrophil Chemotactic Activating Polypeptides, London, UK in 1989. The discovery of IL-8 prompted us to also purify and molecularly clone the cDNA of MCAF/MCP-1 responsible for monocyte chemotaxis, and other groups to identify a large family of chemotactic cytokines capable of attracting other types of leukocytes. In 1992, most of the investigators contributing to the discovery of this new family of chemotactic cytokines gathered in Baden, Austria and agreed to name this family “chemokines” and subsequently established the CXCL/CCL and CXCR/CCR nomenclature. The discovery of chemokines resulted in solving the long-time enigma concerning the mechanism of cell type specific leukocyte infiltration into inflamed tissues and provided a molecular basis for immune and hematopoietic cell migration and interactions under physiological as well as pathological conditions.
To our surprise based on its recently identified multifunctional activities, IL-8 has evolved from a neutrophil chemoattractant to a promising therapeutic target for a wide range of inflammatory and neoplastic diseases. IL-8 was initially characterized as a chemoattractant of neutrophils engaged in acute inflammation and then discovered to also be chemotactic for endothelial cells with a major role in angiogenesis. These two activities of IL-8 foster its stimulatory effect on tumor growth. This is abetted by recent additional discoveries showing that IL-8 has stimulatory effects on stem cells and can therefore directly promote the growth of receptor expressing cancer stem cells. IL-8 by interacting with bone marrow stem/progenitor cells has also the capacity to mobilize and release hematopoietic cells into the peripheral circulation. This includes the mobilization of neutrophilic myeloid-derived suppressor cells (N-MDSC) to infiltrate into tumors and thus further promotes the immune escape of tumors. Finally, the capacity of IL-8 to induce trans-differentiation of epithelial cancer cells into mesenchymal phenotype (EMT) increases the malignancy of tumors by promoting their metastatic spread and resistance to chemotherapeutics and cytotoxic immune cells. These observations have stimulated considerable current efforts to develop receptor antagonists for IL-8 and humanized anti-IL-8 antibody for the therapy of cancer, particularly in combination with immune checkpoint inhibitors, such as anti-PD-1/PD-L1 antibodies.
Nanotechnology based advanced therapeutic strategies for targeting interleukins in chronic respiratory diseases
2021, Chemico-Biological Interactions
Both communicable and non-communicable chronic respiratory conditions have accorded for suffering of millions of people of all ages and stated to be leading cause of death, morbidity, economic and social pressures, and disability-adjusted life-years (DALYs) worldwide. These illnesses impair patient's health and negatively impacts families and society, particularly in low and middle-income countries. Chronic respiratory diseases (CRDs) affect different organs of respiratory system, involving airways, parenchyma, and pulmonary vasculature. As the number of respiratory diseases are exponentially escalating but still the stakeholders are not paying attention towards its serious complications. Currently, the treatment being used primarily focusses only on alleviating symptoms of these illness rather delivering the therapeutic agent at target site for optimal care and/or prevention. Lately, extensive research is being conducted on airways and systemic inflammation, oxidative stress, airway, or parenchymal rehabilitation. From which macrophages, neutrophils, and T cells, as well as structural cells as fibroblasts, epithelial, endothelial, and smooth muscle cells have been found to be active participants that are involved in these chronic respiratory diseases. The pathogenesis of all these chronic respiratory diseases gets caused differently via mediators and proteins, including cytokines, chemokines, growth factors and oxidants. Presently, the target of prescription therapies is to reduce the inflammation of airways and relieve the airway contraction. In all studies, cytokines have been found to play an imperative role in fostering chronic airway inflammation and remodelling. Owing to the limitations of conventional treatments, the current review aims to summarize the current knowledge about the chronic respiratory disease and discuss further about the various conventional methods that can be used for treating this ailment. Additionally, it also highlights and discusses about the advanced drug delivery system that are being used for targeting the interleukins for the treatment of CRDs.

View all citing articles on Scopus

^∗: The British Cytokine Group BCG is a multidisciplinary research group for those in the UK who are interested in cytokines - from molecular biology to human clinical trials. One day meetings, which aim to present the best and the latest UK cytokine research, are held twice a year. Further information from F. Balkwill.

View full text

reviewThe cytokine network

Abstract

Biochem. Biophys. Res. Commun.

Blood

Immunol. Today

Immunol. Today

Hum. Immunol.

Immunol. Today

Cell. Immunol.

Immunol. Today

Cell

Nature

Lab. Invest.

Cytokines in Cancer Therapy

J. Immunol.

J. Exp. Med.

Nature

Blood

J. Cell Biol.

Cancer Res.

Science

J. Immunol.

Int. J. Cancer

New Engl. J. Med.

Cancer Res

Nature

Annu. Rev. Immunol.

J. Immunol.

J. Immunol.

FASEB J.

J. Natl Cancer Inst.

Eur. J. Immunol.

J. Clin. Invest.

Lymphokines

J. Clin. Invest.

Int. J. Cancer

Cancer Res.

J. Immunol.

J. Immunol.

J. Natl Cancer Inst.

J. Exp. Med.

Clin. Exp. Immunol.

J. Exp. Med.

J. Exp. Med.

J. Immunol.

review
The cytokine network